Shares of Regenxbio (RGNX) were surging premarket Monday after the biotechnology company reported new, positive data from the phase I/II portion of a study evaluating RGX-202 gene therapy for Duchenne muscular dystrophy.
The company also said the gene therapy has advanced to a pivotal stage with a first patient dosed. RGX-202 will now be evaluated in the pivotal trial in about 30 patients aged 1 and older, according to Regenxbio.
Regenxbio also said it is "quickly advancing" the gene therapy toward a biologics license application filing in 2026.
Price: 9.19, Change: +0.40, Percent Change: +4.60
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。